ACKB:EURONEXT BRUSSELSAckermans & van Haaren NV Analysis
Data as of 2026-07-02 - not real-time
€278.80
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ackermans & Van Haaren trades at €278.8, roughly 27% above the DCF‑derived fair value of €218, indicating a short‑term premium. The stock’s trailing P/E of 15.4 is well below the industry average of 31.8, suggesting relative valuation appeal, while the RSI sits at 48 and the MACD histogram has turned negative, hinting at a possible near‑term pullback despite the overall bullish trend and price staying above the 20‑ and 50‑day SMAs. Dividend sustainability looks strong – a €4.60 payout (1.61% yield) with a modest 21% payout ratio is backed by solid operating cash flow of €1.0 bn and a free cash flow of €540 m. Volatility remains elevated at 22.5% over 30 days, but the low beta of 0.40 points to limited market‑wide sensitivity.
The recent shareholder meeting confirmed a €4.60 dividend and the Q1 trading update highlighted a “strong start” and reaffirmed guidance, underscoring confidence in earnings continuity. With a diversified business spanning marine engineering, private banking, real estate and energy, the company benefits from multiple cash‑generating streams, though revenue contracted 7.3% YoY. The balance sheet shows a debt‑to‑equity of 30.5%, manageable given ample cash reserves of €2.2 bn. Overall, the stock appears overvalued on a price‑based basis, yet its fundamentals and dividend profile provide a cushion for longer‑term investors.
The recent shareholder meeting confirmed a €4.60 dividend and the Q1 trading update highlighted a “strong start” and reaffirmed guidance, underscoring confidence in earnings continuity. With a diversified business spanning marine engineering, private banking, real estate and energy, the company benefits from multiple cash‑generating streams, though revenue contracted 7.3% YoY. The balance sheet shows a debt‑to‑equity of 30.5%, manageable given ample cash reserves of €2.2 bn. Overall, the stock appears overvalued on a price‑based basis, yet its fundamentals and dividend profile provide a cushion for longer‑term investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price trading above fair value
- Bearish MACD crossover
- Elevated short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong dividend yield with low payout ratio
- Stable cash flow and manageable debt
- Confirmed earnings guidance for 2026
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Diversified business model across multiple sectors
- Attractive relative valuation versus industry peers
- Sustainable dividend and solid balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth-7.30%
Profit Margin9.94%
P/E Ratio15.4
ROE11.02%
ROA2.43%
Debt/Equity30.48
P/B Ratio1.6
Op. Cash Flow€1.0B
Free Cash Flow€540.6M
Industry P/E31.8
Technical Analysis
TrendBullish
RSI48.2
Support€262.00
Resistance€290.40
MA 20€279.27
MA 50€278.85
MA 200€252.05
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
Fair Value€218.12
Target Price€304.14
Upside/Downside9.09%
GradeOvervalued
TypeValue
Dividend Yield1.61%
Risk Assessment
Beta0.40
Volatility22.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.